CELC vs. STOK, CRBP, COGT, STTK, WVE, SLDB, DNTH, ACRV, MACK, and IMMP
Should you be buying Celcuity stock or one of its competitors? The main competitors of Celcuity include Stoke Therapeutics (STOK), Corbus Pharmaceuticals (CRBP), Cogent Biosciences (COGT), Shattuck Labs (STTK), Wave Life Sciences (WVE), Solid Biosciences (SLDB), Dianthus Therapeutics (DNTH), Acrivon Therapeutics (ACRV), Merrimack Pharmaceuticals (MACK), and Immutep (IMMP). These companies are all part of the "medical" sector.
Stoke Therapeutics (NASDAQ:STOK) and Celcuity (NASDAQ:CELC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking.
Stoke Therapeutics' return on equity of -54.74% beat Celcuity's return on equity.
Celcuity received 226 more outperform votes than Stoke Therapeutics when rated by MarketBeat users. However, 72.39% of users gave Stoke Therapeutics an outperform vote while only 66.60% of users gave Celcuity an outperform vote.
In the previous week, Stoke Therapeutics had 5 more articles in the media than Celcuity. MarketBeat recorded 5 mentions for Stoke Therapeutics and 0 mentions for Celcuity. Celcuity's average media sentiment score of 0.52 beat Stoke Therapeutics' score of 0.00 indicating that Stoke Therapeutics is being referred to more favorably in the media.
Stoke Therapeutics presently has a consensus target price of $19.63, indicating a potential upside of 64.23%. Celcuity has a consensus target price of $29.00, indicating a potential upside of 89.42%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Celcuity is more favorable than Stoke Therapeutics.
Celcuity has lower revenue, but higher earnings than Stoke Therapeutics. Celcuity is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.
Stoke Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Celcuity has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.
63.3% of Celcuity shares are owned by institutional investors. 12.3% of Stoke Therapeutics shares are owned by company insiders. Comparatively, 24.3% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Celcuity beats Stoke Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Celcuity News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CELC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celcuity Competitors List
Related Companies and Tools
